Biosimilars Development Strategies
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 20 May 2025 | Viewed by 669
Special Issue Editors
Interests: biosimilars; mRNA delivery; AI-driven protein structure; bioequivalence; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Biosimilars, also known as similar biological medicinal products or biosimilars, are biological products that are highly similar to an already approved biological medicine in terms of quality, safety, and efficacy. These products may exhibit minor differences with regard to their non-active components compared to the reference medicine, but show no substantial differences in terms of safety, purity, and potency. The development of biosimilars aims to reduce the cost of healthcare for patients and improve their access to biological therapies. The FDA defines a generic drug as one that is identical—or bioequivalent—to a branded drug in terms of its dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.
This Special Issue focuses on the development of biosimilars, a rapidly evolving field with an immense potential to enhance patients’ access to affordable biological therapies. It explores aspects related to the design, manufacturing, and analytical characterization of biosimilars.
This Special Issue aims to provide a comprehensive overview of the latest advancements and challenges associated with the development of biosimilars. It will serve as a valuable resource for researchers and developers interested in this critical area of biopharmaceutical science.
Dr. Sarfaraz K. Niazi
Dr. Sesselja S. Ómarsdóttir
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biosimilars
- generic medicines
- drug development
- biosimilar development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
